Important information for cardiac rehabilitation providers re COVID-19

We recognise that many centre-based cardiac rehabilitation services have been disrupted in response to mechanisms deployed to manage and contain the spread of COVID-19.

As a clinically proven model of care that enables the remote provision of cardiac rehabilitation to patients in their home, we are keen to work with the network of providers to support the continuity of care for patients throughout this time.

The Cardihab model enables staff to work from home, as well as patients receiving care from home, thereby reducing the risk of contamination and spread.

Remote cardiac rehabilitation may be accessible under Medicare via the Federal Government’s COVID-19 health package.

If you have concerns around the continuity and access to cardiac rehabilitation that you think we could assist with, please contact us.

Cardihab helps Medibank tackle cardiac mortality

Patient using Cardihab app

Cardihab is proud to support Medibank in a trial aiming to improve access to cardiac rehabilitation and prevent cardiac patients from experiencing a second serious event.

SmartCR, Cardihab’s digital cardiac rehabilitation app, will be provided to patients who participate in the Medibank Heart Health at Home trial.  By providing phone-based counselling in combination with SmartCR, the Heart Health at Home trial will allow trial participants to access cardiac rehabilitation from the comfort and convenience of their home rather than a hospital setting.

CEO of Cardihab, Helen Souris, said involvement in the Medibank trial was an important milestone toward meeting the company’s vision of helping patients reach optimal health when at risk of, or living with, heart disease.

“Receiving timely access to cardiac rehabilitation services is a significant challenge for people who have experienced an acute cardiac event,” Helen said. “We are proud to be supporting Medibank in their endeavours to make a difference on such an important aspect of cardiac care.”

The Medibank Heart Health at Home trial for customers will include:

• Clinical care coordinators (such as a cardiac nurse or physiotherapist) to provide one to one support through weekly telephone consultations.

• Access to the Cardihab smart phone app to provide health and exercise monitoring, motivational and educational materials, and medication management tools.

• Exercise targets based on recommended activity post cardiac procedure.

Cardiovascular disease remains Australia’s largest killer, accounting for 44,000 deaths in 2017 and 1.1 million hospitalisations a year. It is expected to cost Australia $22 billion by 2032-33.[i]

People have already experienced a serious event, such as an acute heart attack, are at higher risk of suffering another serious event, with a Canadian study showing 61.7% were readmitted within a year.[ii]

Cardiac rehabilitation, a medically supervised exercise and information program for people who have had heart surgery or a serious heart event, has been shown to achieve a 26% reduction in mortality and an 18% reduction in readmissions, as well as quality of life benefits.[iii] Despite this, less than 30% of eligible patients participate.[iv]

In a clinical trial, Cardihab’s digital cardiac rehabilitation solution, which allows users to participate in a program in the comfort of their own home, demonstrated significantly higher rates vs traditional hospital-based cardiac rehab of:

  • uptake (80% vs 62%),
  • adherence (94% vs 68%) and
  • completion (80% vs 47%)[v]

In addition, the home-based program was as effective in improving physiological and psychological health outcomes as traditional cardiac rehabilitation.

[i] Australian Bureau of Statistics 2018, Causes of Death 2017, ABS cat. no. 3303.0.

[ii] Southern DA, Ngo J, Martin BJ, Galbraith PD, Knudtson ML, Ghali WA, James MT and Wilton SB. Characterizing types of readmission after acute coronary syndrome hospitalization: implications for quality reporting. J Am Heart Assoc 2014;3:e001046

[iii] Anderson L, et al. Exercise – Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta – Analysis. J Am Coll Cardiol. 2016 Jan 5; 67(1):1 – 12. dol:10.1016/j.jacc.2015.10.044

[v] Varnfield M, Karunanithi M, Lee C-K, et al. Heart 2014;100:1770–1779.

[iv] Clark RA, Conway A, Poulsen V, et al. Alternative models of cardiac rehabilitation: a systematic review. Eur J Prev Cardiol 2013; 0 (00), 1 – 40

The health-related startups emerging in Australia from scientific research

David Burt

David Burt, CSIRO‘s Executive Manager ON Innovation Program, was recently interviewed in Business Insider about some of the health-related startups coming out of scientific research in Australia, including Cardihab.

Cardihab’s Digital Cardiac Rehabilitation platform was scientifically validated in a world first, randomised controlled trial (RCT) by researchers from CSIRO and The Prince Charles Hospital via the Australian E-Health Research Centre.  The ON Accelerator program was an important step in commercialisation as it provided an opportunity to pursue customer and investor interest in the research.

If you’re a founder looking to launch your health-related startup, the ON Innovation Program could be for you.

Cardihab featured in Qantas Spirit of Australia Magazine

Qantas Spirit of Australia Magazine

Cardihab has been recognised as one of the leading digital health platforms emerging in Australia in the November 2017 issue of the Qantas Spirit of Australia magazine.

The QBusiness section feature article describes how Cardihab’s evidence-based cardiac rehabilitation product was developed from world-first research conducted in Queensland by the Australian E-Health Research Centre. Cardihab then completed the CSIRO ON and HCF Catalyst startup accelerator programs, and recently gained investment from investors including Uniseed and Slingshot Investments.  The article includes interviews with CSIRO Chief Executive Officer, Dr Larry Marshall, and Cardihab Chief Technology Officer, Simon McBride.

The Spirit of Australia magazine is available for download at, with physical copies on board Qantas flights and in lounges during November 2017.

“On the road again” for ACRA

Cardihab CEO Gus Taddeo & vendor exhibit at ACRA NSW/ACT 2017 annual scientific meeting

The Australian Cardiovascular Health and Rehabilitation Association (ACRA) is one of the leading organisations for cardiac rehabilitation professionals in Australia. ACRA has a vibrant membership who are enthusiastic about professional development and their enthusiasm is shown in the quality, frequency and attendance at education events.

Cardihab is proud to have sponsored the ACRA 2017 Annual Scientific Meeting and we’re “on the road again” and sponsoring, exhibiting and speaking at three State education events over two weeks. Our road trip started last week with a vendor exhibit and sponsorship of the ACRA NSW/ACT conference in Sydney.

This week Cardihab is in Melbourne for the Victorian ACRA Education Day, where we are a Bronze sponsor and exhibitor, and on the Sunshine Coast for the ACRA Queensland/Heart Foundation Secondary Prevention in Cardiology Symposium where we are a Silver sponsor, exhibitor and invited speaker.


Cardihab featured on Sky News Business

Cardihab Director and Uniseed CEO Dr Peter Devine was recently interviewed on Sky News Business. Uniseed is a venture capital fund operated in partnership by the Universities of Melbourne, Queensland, New South Wales and Sydney, and the CSIRO. The fund has a mandate to commercialise partner research by targeting investment in highly promising technologies. Dr Devine describes why Uniseed invested in Cardihab and its plans for growth.

Cardihab Cardiac Rehab App spun out of CSIRO eHealth division

Brisbane, Australia, September 19th 2017: An Australian solution to dramatically improve recovery from a heart attack today became reality.

Cardihab’s technology platform was developed by scientists at the Australian eHealth Research Centre (AEHRC), a joint venture between CSIRO and the Queensland Government. Cardihab was spun-out from CSIRO after raising venture capital investment of $1.35 million in the new company.

In Australia someone has a heart attack every nine minutes, however less than one third of survivors follow through with cardiac rehabilitation, resulting in up to a 50% chance of being readmitted to hospital in the following year.

Cardihab is a smartphone app connected to a clinic based portal, used for remote patient management following a cardiac event. The app gives clinicians the ability to deliver more convenient, flexible and engaging cardiac rehabilitation meaning better outcomes for patients, clinicians and health service administrators.

Cardihab’s model of care is backed by a randomised control trial that was conducted by CSIRO and the Metro North Brisbane Health and Hospital Service, and published in the international journal Heart. The trial demonstrated that the Cardihab model of care was clinically equivalent to normal care, but significantly improved patient uptake, adherence and completion of cardiac rehabilitation.

Cardihab was able to demonstrate there was no additional benefit for patients who receive face to face care, compared to patients whose cardiac rehabilitation was carried out by a clinician remotely.

Cardihab Chief Technology Officer Simon McBride was part of the team that has been developing and trialling the technology while undertaking research at the AEHRC. “Today’s investment gives us the platform on which to build the company and make a difference to the lives of millions of Australians,” McBride said.

Of the $1.35million invested in Cardihab, $500,000 has come from Uniseed, a venture fund operating at the Universities of Melbourne, New South Wales, Sydney, Queensland and CSIRO.

The remaining investment is made by private cardiology groups, and existing Cardihab shareholder Slingshot Investments as manager of the Slingshot Venture Fund.

Cardihab benefited from participation in CSIRO’s AcceleratiON and Slingshot’s HCF Catalyst accelerator programs and is led by recently appointed CEO Gus Taddeo, who was formerly Managing Director of Cook Medical Australia.


Cardihab a Gold Sponsor at ACRA 2017 conference

Cardihab is proud to announce its Gold Sponsorship of the Australian Cardiovascular Health and Rehabilitation Association 27th Annual Scientific Meeting to be held at the Rendezvous Hotel Scarborough in Perth, Western Australia, from the 7-9 August 2017.

The ACRA 2017 program includes a world class list of speakers including Associate Professor Tom Briffa (University of Western Australia), Professor David Dunstan (Baker Heart and Diabetes Institute), Dr Rolf Gomes (Heart of Australia) and many others. Cardihab is hosting a breakfast symposium on digital cardiac rehabilitation (7:30-8:15am, Tuesday 8 August, Preston BC room), sponsoring the Health Technolgies workshop (3:15-4:15pm, Tuesday 8 August, Mentelle room) and exhibiting throughout the conference.

Registrations are now open and we look forward to seeing you in Perth!